Domestic pharmaceutical companies are seeking market entry not through simple imitation, but with differentiated technologies. G2GBIO is developing an obesity treatment platform that can be administered once a month, with plans to enter clinical trials next year. This innovative approach maximizes patient convenience based on proprietary technology that sustains drug efficacy over a long period. Hanmi Pharmaceutical's efpeglenatide is also expected to gain an advantage in terms of safety, with a lower incidence of side effects compared to its competitor, Wegovy. The drive to reduce side effects, maintain long-term efficacy, and even develop oral obesity drugs demonstrates that K-bio's technological capabilities are moving beyond mere pursuit to a stage of leading innovation. Such R&D innovation by domestic biopharmaceutical companies opens up the possibility for Korea to emerge as a key player in the global obesity treatment market. Currently, the global obesity treatment market is dominated by Novo Nordisk and Eli Lilly, but surging demand continues to lead to supply shortages. This presents a golden opportunity for latecomers to enter the market, which is why Korean pharmaceutical companies are attracting significant investor attention in the Pre-IPO stage. If Korea's obesity treatments secure global approval and enter overseas markets in the future, they are expected to replicate successful technology transfer and royalty distribution models, such as that of Leclaza.